Blazing Star Merger Sub completes Walgreens debt tender offer
On Wednesday, Cantor Fitzgerald analysts maintained their Overweight rating on X4 Pharmaceuticals (NASDAQ:XFOR) with a steady price target of $3.00, significantly above the current stock price of $0.26. According to InvestingPro data, analyst targets range from $1.50 to $4.00, with a strong consensus recommendation of 1.4 (Buy). The firm’s analysts pointed out that while investor sentiment is generally positive regarding the company’s potential in the CN market, X4 Pharmaceuticals has been facing challenges due to financial concerns and a lack of immediate catalysts that could drive stock performance. The stock has declined over 82% in the past year.
The slow launch of XOLREMDI, X4’s therapeutic offering, has not gone unnoticed by investors, who seem to be more interested in the company’s prospects in the CN market rather than its commercial performance. According to Cantor Fitzgerald, XOLREMDI is considered a "show-me commercial story," implying that the market is waiting for more evidence of its commercial success before fully committing. InvestingPro analysis reveals that while the company maintains a healthy current ratio of 3.41, it’s quickly burning through cash - a crucial metric for investors monitoring the company’s commercial progress.
Despite these challenges, the analysts acknowledged that X4 Pharmaceuticals has made strategic moves to mitigate financial risks, particularly by out-licensing XOLREMDI in various territories. This strategy is seen as a positive step towards supporting the company’s balance sheet and providing some stability amidst the pressures on the stock.
The reiteration of the Overweight rating and the $3.00 price target reflects Cantor Fitzgerald’s view that X4 Pharmaceuticals still holds potential for growth despite the current headwinds. The firm’s analysts seem to believe that the company’s strategic licensing efforts could eventually pay off, helping to alleviate some of the financial strain and potentially leading to a more favorable outlook for XOLREMDI’s commercial trajectory.
In other recent news, X4 Pharmaceuticals has reported its fourth-quarter 2024 earnings, revealing an earnings per share (EPS) of -$0.20, which did not meet the forecast of -$0.16. However, the company exceeded revenue expectations, posting $1.43 million against a projected $990,710. Brookline Capital Markets maintained a Buy rating on X4 Pharmaceuticals with a $4.00 price target, noting the company’s product, Xolremdi, surpassed sales estimates with $1.4 million in revenue. Meanwhile, Stifel adjusted its price target for X4 Pharmaceuticals from $4.00 to $3.00, maintaining a Buy rating but adopting a more cautious stance on the commercial prospects of Xolremdi.
The company announced strategic restructuring efforts aimed at reducing annual spending by $30-35 million, which is expected to extend operational funds into the first half of 2026. This move aligns with X4’s focus on advancing mavorixafor for chronic neutropenia treatment. Additionally, X4 Pharmaceuticals is working on completing patient enrollment for the ongoing Phase 3 4WARD trial, with guidance now extended to the second half of 2025. The trial is considered a crucial catalyst for the company’s future, especially as it seeks additional funding to reach the year-end 2026 data announcement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.